14-Day Nose-Only Inhalation Toxicity and Haber's Rule Study of NNK in Sprague-Dawley Rats.

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is one of the key tobacco-specific nitrosamines that plays an important role in human lung carcinogenesis. However, repeated inhalation toxicity data on NNK, which is more directly relevant to cigarette smoking, are currently limited. In the present study, the subacute inhalation toxicity of NNK was evaluated in Sprague Dawley rats. Both sexes (9-10 weeks age; 16 rats/sex/group) were exposed by nose-only inhalation to air, vehicle control (75% propylene glycol), or 0.8, 3.2, 12.5, or 50 mg/kg body weight (BW)/day of NNK (NNK aerosol concentrations: 0, 0, 0.03, 0.11, 0.41, or 1.65 mg/L air) for 1 hour/day for 14 consecutive days. Toxicity was evaluated by assessing body and organ weights; food consumption; clinical pathology; histopathology observations; blood, urine, and tissue levels of NNK, its major metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and their glucuronides (reported as total NNK, tNNK, and total NNAL, tNNAL, respectively); O6-methylguanine DNA adduct formation; and blood and bone marrow micronucleus frequency. Whether the subacute inhalation toxicity of NNK followed Haber's Rule was also determined using additional animals exposed 4 hours/day. The results showed that NNK exposure caused multiple significant adverse effects, with the most sensitive endpoint being non-neoplastic histopathological lesions in the nose. The lowest-observed-adverse-effect level (LOAEL) was 0.8 mg/kg BW/day or 0.03 mg/L air for 1 hour/day for both sexes. An assessment of Haber's Rule indicated that 14-day inhalation exposure to the same dose at a lower concentration of NNK aerosol for a longer time (4 hours daily) resulted in greater adverse effects than exposure to a higher concentration of NNK aerosol for a shorter time (1 hour daily).

[1]  R. Mittelstaedt,et al.  Toxicokinetic and Genotoxicity Study of NNK in Male Sprague-Dawley Rats Following Nose-Only Inhalation Exposure, Intraperitoneal Injection, and Oral Gavage. , 2021, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  M. Saruta,et al.  The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis , 2020, Pancreas.

[3]  R. Mittelstaedt,et al.  Evaluation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) mutagenicity using in vitro and in vivo Pig-a assays. , 2019, Mutation research. Genetic toxicology and environmental mutagenesis.

[4]  M. Bryant,et al.  Rapid quantitation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in rat urine using ultra-fast liquid chromatography mass spectrometry (UFLC/MS/MS) , 2018 .

[5]  Stanton A. Glantz,et al.  E-Cigarettes , 2014, Circulation.

[6]  J. T. Macgregor,et al.  Diethylnitrosamine genotoxicity evaluated in sprague dawley rats using Pig‐a mutation and reticulocyte micronucleus assays , 2014, Environmental and molecular mutagenesis.

[7]  M. Oldham,et al.  Toxicological evaluation of aerosols of a tobacco extract formulation and nicotine formulation in acute and short-term inhalation studies , 2014, Inhalation toxicology.

[8]  S. Hamada,et al.  Persistence and accumulation of micronucleated hepatocytes in liver of rats after repeated administration of diethylnitrosamine. , 2013, Mutation research.

[9]  Juan Wang,et al.  Simultaneous determination of NNK and its seven metabolites in rabbit blood by hydrophilic interaction liquid chromatography–tandem mass spectrometry , 2013, Analytical and Bioanalytical Chemistry.

[10]  M. Hayashi,et al.  Development of a repeated-dose liver micronucleus assay using adult rats: an investigation of diethylnitrosamine and 2,4-diaminotoluene. , 2012, Mutation research.

[11]  L. Krsmanović,et al.  Assessment of genotoxicity induced by 7,12‐dimethylbenz(a)anthracene or diethylnitrosamine in the Pig‐a, micronucleus and Comet assays integrated into 28‐day repeat dose studies , 2011, Environmental and molecular mutagenesis.

[12]  C. Rousselle,et al.  Haber's rule duration adjustments should not be used systematically for risk assessment in public health decision-making. , 2011, Toxicology letters.

[13]  Hua-Chuan Zheng,et al.  NNK-Induced Lung Tumors: A Review of Animal Model , 2011, Journal of oncology.

[14]  M. Schuler,et al.  Evaluation of a modified CD71 MicroFlow method for the flow cytometric analysis of micronuclei in rat bone marrow erythrocytes. , 2010, Mutation research.

[15]  J. Chen,et al.  Deviations from Haber's Law for multiple measures of acute lung injury in chlorine-exposed mice. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  Patrick Maisonneuve,et al.  Epidemiology of Pancreatic Cancer: An Update , 2010, Digestive Diseases.

[17]  Sven Ove Hansson,et al.  Assessment factors for extrapolation from short-time to chronic exposure--are the REACH guidelines adequate? , 2009, Toxicology letters.

[18]  Jian-Min Yuan,et al.  Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. , 2009, Cancer research.

[19]  S. Hecht,et al.  Progress and challenges in selected areas of tobacco carcinogenesis. , 2008, Chemical research in toxicology.

[20]  S. Hecht,et al.  Cigarette smoking: cancer risks, carcinogens, and mechanisms , 2006, Langenbeck's Archives of Surgery.

[21]  R. G. Klein,et al.  Systemic genotoxic effects of tobacco-related nitrosamines following oral and inhalational administration to Sprague-Dawley rats , 1992, The clinical investigator.

[22]  Stephen S. Hecht,et al.  Tobacco carcinogens, their biomarkers and tobacco-induced cancer , 2003, Nature Reviews Cancer.

[23]  N. Bunce,et al.  Haber's Rule: The Search for Quantitative Relationships in Toxicology , 2003 .

[24]  S. Hecht,et al.  Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. , 2002, Carcinogenesis.

[25]  J. Guttenplan,et al.  Mutagenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosonornicotine in lacZ upper aerodigestive tissue and liver and inhibition by green tea. , 2001, Carcinogenesis.

[26]  D W Gaylor,et al.  The use of Haber's law in standard setting and risk assessment. , 2000, Toxicology.

[27]  S. Stellman,et al.  Doses of nicotine and lung carcinogens delivered to cigarette smokers. , 2000, Journal of the National Cancer Institute.

[28]  J. Guttenplan,et al.  Mutagenesis induced by oral carcinogens in lacZ mouse (MutaMouse) tongue and other oral tissues. , 1999, Carcinogenesis.

[29]  L. Ryan,et al.  Dose-rate effects of ethylene oxide exposure on developmental toxicity. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  S. Hecht,et al.  Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.

[31]  Walter A. Korfmacher,et al.  Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. , 1997, Journal of chromatography. A.

[32]  W Slob,et al.  Conversion factors estimating indicative chronic no-observed-adverse-effect levels from short-term toxicity data. , 1996, Regulatory toxicology and pharmacology : RTP.

[33]  S. Amin,et al.  Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats. , 1990, Carcinogenesis.

[34]  S. Belinsky,et al.  Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 1990, Cancer research.

[35]  P. Padma,et al.  Mutagenic and cytogenetic studies of N'-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 1989, Cancer letters.

[36]  S. Amin,et al.  Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. , 1988, Cancer research.

[37]  P. M. Moody Human smoking patterns and smoke deliveries. , 1984, The International journal of the addictions.

[38]  S. Hecht,et al.  Tissue distribution of the tobacco-specific carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and its metabolites in F344 rats. , 1983, Cancer research.

[39]  J. T. Young Histopathologic examination of the rat nasal cavity. , 1981, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[40]  S. Hecht,et al.  Assessment of tobacco-specific N-nitrosamines in tobacco products. , 1979, Cancer research.

[41]  F. J. Miller,et al.  Influence of exposure mode on the toxicity of NO2. , 1979, Environmental health perspectives.